Cabometyx

About Royalty Pharma

Founded in 1996, Royalty Pharma pioneered the royalty pharma asset class by providing non-dilutive capital to pharmaceutical innovators. The company has deployed over $19 billion to acquire royalty interests in leading medicines across multiple therapeutic areas. As a publicly-traded company on NASDAQ, Royalty Pharma generates revenue from royalty payments on successful drugs while helping fund the next generation of medical breakthroughs.

About Ipsen

Ipsen is a well-established French biopharmaceutical company that has evolved from its 1986 founding to become a global leader in specialty care medicines. The company focuses on areas of high unmet medical need across oncology, rare diseases, and neuroscience, with particular expertise in neuroendocrine tumors, rare liver conditions like PBC, and neurological disorders including spasticity. Ipsen's strategy emphasizes targeted innovation and strategic partnerships to accelerate drug development and expand their pipeline. The company has demonstrated strong financial performance with consistent growth and maintains a robust balance sheet to support continued R&D investments and pipeline expansion.

Therapeutic Areas

Other Renal cell carcinoma Drugs